BioLight Life Sciences Ltd. (IL:BOLT)
TASE:BOLT
Want to see IL:BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
371.40
-0.16(-2.50%)
At close: 4:00 PM EST
371.40
-0.16(-2.50%)
Day’s Range― - ―
52-Week Range209.20 - 636.70
Previous CloseN/A
Volume1.67K
Average Volume (3M)11.86K
Market Cap
₪22.71M
Enterprise Value9.92M
Total Cash (Recent Filing)₪23.65M
Total Debt (Recent Filing)₪772.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Solvency RiskVery low debt-to-equity materially reduces refinancing and solvency risk over the medium term. This structural balance-sheet strength gives management more time to execute R&D or partnership strategies without immediate pressure from creditors, lowering fixed financing costs and downside risk.
Meaningful Equity CushionDespite declines, a positive shareholders' equity balance (~34.4M in 2025) remains a tangible capital buffer. That capital base can absorb losses in the near-to-medium term and supports the company’s ability to continue operations and pursue incremental R&D or licensing activities before needing immediate recapitalization.
Lean Operating FootprintA very small employee base implies lower ongoing fixed payroll and overhead, which structurally reduces cash burn relative to larger peers. For a pre-commercial, R&D-focused biotech this lean footprint increases operational flexibility and extends runway per unit of funding, aiding durability of operations.
Bears Say
Persistent Cash BurnConsistent, deep negative operating and free cash flow indicates the business cannot self-fund growth or operations. Over months this necessitates external financing, increases dilution risk, and erodes the equity cushion, constraining strategic optionality and making long-term execution dependent on capital markets or partners.
Revenue Collapse / AbsenceA drop to zero reported revenue signals pre-commercial status or loss of commercial traction. Without recurring revenue, the company cannot scale operating leverage to cover fixed R&D and G&A costs, leaving business viability contingent on future product approvals, partnerships, or fundraising rather than internal cash generation.
Structural Operating LossesPersistent operating and net losses over multiple years mean returns on capital are negative and equity is being eroded. This undermines long-term financial sustainability, raises cost of capital, and limits ability to invest organically, making durable recovery dependent on successful development milestones or external financing.
BOLT FAQ
What was BioLight Life Sciences Ltd.’s price range in the past 12 months?
BioLight Life Sciences Ltd. lowest stock price was 209.20 and its highest was 636.70 in the past 12 months.
What is BioLight Life Sciences Ltd.’s market cap?
BioLight Life Sciences Ltd.’s market cap is ₪22.71M.
When is BioLight Life Sciences Ltd.’s upcoming earnings report date?
BioLight Life Sciences Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 105 days.
How were BioLight Life Sciences Ltd.’s earnings last quarter?
BioLight Life Sciences Ltd. released its earnings results on Apr 01, 2026. The company reported -67.2 earnings per share for the quarter, missing the consensus estimate of N/A by -67.2.
Is BioLight Life Sciences Ltd. overvalued?
According to Wall Street analysts BioLight Life Sciences Ltd.’s price is currently Overvalued.
Does BioLight Life Sciences Ltd. pay dividends?
BioLight Life Sciences Ltd. does not currently pay dividends.
What is BioLight Life Sciences Ltd.’s EPS estimate?
BioLight Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLight Life Sciences Ltd. have?
BioLight Life Sciences Ltd. has 9,079,270 shares outstanding.
What happened to BioLight Life Sciences Ltd.’s price movement after its last earnings report?
BioLight Life Sciences Ltd. reported an EPS of -67.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioLight Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IL:BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLight Life Sciences Ltd.
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.